Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection (PR Newswire)

NEW YORK, Sept. 7, 2023 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”), today announced it has released positive interim data from the multicenter, CLinical Utility of EsoGuard (CLUE) study. This is the Company’s first report of prospective data from multiple physicians demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer; and supplements its recently released positive data from a retrospective analysis of EsoGuard’s clinical utility in firefighters.